SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs lead product, DefenCath, could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and revenue. Traders dispute how definitive DaVitas preliminary outlook is, pointing to CMSs published rate estimates and arguing that greater use could offset lower reimbursement.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention ahead of its upcoming earnings, with traders debating whether growth will support the stock after a volatile pullback. Bullish traders expect a strong report, while others cite valuation and unverified concerns about security issues in third-party apps as reasons for caution.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal Q4 results are driving discussion: a modest earnings beat and resilient payment activity are tempered by a slower-growth outlook, prompting a sell-the-news reaction. Bulls point to durable consumer spending and cross-border activity, while skeptics argue the results and guidance fall short of expectations.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS, prompting debate over how much competition could affect its sales. Traders are split: some see the rival as a serious threat, while others emphasize Precigens full approval and commercial head start, alongside questions about Inovios accelerated-approval requirements and ability to launch.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and tech-sector selloff has driven attention to TQQQ, with traders citing worries about AI spending and earnings alongside inflation, interest-rate, and geopolitical risks. The community is split between buying the steep dip for a possible rebound and warning that further losses may follow.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury proxy for Hyperliquids HYPE token, with traders linking its swings to HYPEs rally and the broader ecosystems growth. Bulls see room for a catch-up move or short squeeze, while bears point to share issuance and dilution as reasons PURR has lagged the token.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys strong quarterly results and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling a rally to record highs. Bulls point to continued growth in its obesity-drug franchise, while skeptics highlight the trimmed profit outlook, rich valuation, and weaker-than-expected Foundayo sales.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a 52-week high as traders anticipate its Q3 results and continued BRIUMVI growth; some attribute the move to earnings expectations, while others speculate about a buyout or short covering. No acquisition has been confirmed, and the earnings date remains unconfirmed.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results, led by strong parks performance and improving streaming profitability, have renewed optimism about Disneys turnaround under new leadership. Traders are debating whether those business trends can lift the stock after its muted, range-bound performance.

Internet Computer (ICP) is a cryptocurrency launched in 2021. Internet Computer has a current supply of 558,194,898.12638538. The last known price of Internet Computer is 2.5370221 USD and is up 5.18 over the last 24 hours. It is currently trading on 447 active market(s) with $63,762,762.22 traded over the last 24 hours. More information can be found at https://internetcomputer.org/.

Internet Computer

Discussion centers on ICPs sovereign-cloud and AI infrastructure ambitions, including posts about a Pakistan national chat app beta and potential government adoption. Bulls view these as signs of real-world utility, while skeptics point to weak adoption, token-supply concerns and prolonged underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's  What You Should Know

The mean of analysts' price targets for Zenas BioPharma, Inc. (ZBIO) points to a 77.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

Key PointsCEO Leon Moulder acquired 60,000 shares for a total value of approximately $1.01 million on May 18, 2026...

Tuesday 5/19 Insider Buying Report: ZBIO, ICFI

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

On Monday, Zenas Biopharma's Chief Executive Officer, Leon O. Moulder Jr., made a...

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.7% - Still a Buy?

Zenas BioPharma (NASDAQ:ZBIO) Shares Up 7.7% - Should You Buy...

Thursday 4/30 Insider Buying Report: ZBIO, PDX

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At Zenas Biopharma, a filing with the SEC revealed that on Wednesday, Chief Executi...

Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity

Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity...

Leon Moulder, Jr. Buys 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 25,000 shares of the company's stock in a transaction that occurred on Tuesday, April 28th. The shares were...

Zenas BioPharma (NASDAQ:ZBIO) CEO Acquires $616,700.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 35,000 shares of the stock in a transaction on Wednesday, April 29th. The stock was purchased at an average cost of...

Leon Moulder Jr Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were acquired at an...

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Hold" by Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) has been given an average rating of "Hold" by the nine brokerages that are presently covering the firm, Marketbeat reports. Two investment...

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zenas Biopharma Inc.

Why Is ZBIO Stock Falling Pre-Market Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Zenas stated that the reduction in the risk flares for its drug candidate obexelimab was at 56%, while rival Amgen’s Uplizna delivered an 87% reduction.</li><li>At 27%, obexelimab’s flare rate was also higher than CEO Lonnie Moulder’s expectations, who previously said that it would be at 10%.</li><li>However, Citi stated in a recent note that it remains confident that obexelimab will be approved and recommended investors to look for buying opportunities.</li></ul>Zenas BioPharma Inc. (ZBIO) shares fell nearly 7% in Tuesday’s pre-market session, after declining by around 52% in Monday’s regular trade.The fall in Zenas’ shares comes after the company announced that a Phase 3 Indigo study of its autoimmune disease candidate, obexelimab, met its primary endpoint.However, the results fell short of Zenas CEO Lonnie Moulder’s own expectations, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercebiotech.com/biotech/zenas-indigo-data-leaves-wall-street-feeling-blue-despite-primary-endpoint-hit">report</a> by Fierce Biotech citing Moulder’s comments at a Jefferies event in November 2025. Moulder had said that the flare rate for obexelimab would be closer to 10%, while the company’s head of R&amp;D, Lisa von Moltke, told investors that the flare rate was at 27%, according to the report.Zenas stated that it expects to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. The company stated that its treatment was well-tolerated and that no new safety signals were observed.<h2 class="st-heading-2">Analyst Updates</h2>According to TheFly, analysts at Citi called the pullback on the results of the Phase 3 trials of Indigo an “overreaction.” The firm stated that the selloff has dragged the ZBIO stock below its “ultra-bear case” scenario of $18 per share.Citi stated in its note that it remains confident that obexelimab will be approved and recommended investors to look for buying opportunities. However, the firm trimmed its price target for the ZBIO stock to $43 from $46, while maintaining a ‘Buy’ rating.Morgan Stanley analysts downgraded Zenas to ‘Equal Weight’ from ‘Overweight’, while lowering the price target to $19 from $37. The firm stated that the results from Zenas’ Phase 3 Indigo trials were short of the benchmark set by Amgen Inc.’s (AMGN) Uplizna.Amgen announced in April 2025 that Uplizna was approved by the FDA as a treatment for Immunoglobulin G4-Related Disease (IgG4-RD). The company stated that Uplizna delivered an 87% reduction in the risk of flares compared to a placebo.Zenas stated that its treatment delivered a 56% reduction in the risk of flares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ZBIO">Zenas BioPharma</a> trended in the ‘extremely bullish’ territory at the time of writing.One Stocktwits user stated that now is a good chance to add ZBIO stock and hold for gains, following the selloff on Monday.<stembedurl>https://stocktwits.com/jreddyN/message/640912743</stembedurl>Another user wondered if the stock is slightly oversold.<stembedurl>https://stocktwits.com/Benalish/message/640912422</stembedurl><a href="https://stocktwits.com/symbol/ZBIO">ZBIO stock</a> is down 54% year-to-date, but up 69% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnts-stock-soared-over-80-today-what-fueling-investor-optimism/cmxMp2FR4b6">MNTS Stock Soared Over 80% Today – What’s Fueling Investor Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Zenas Biopharma logo is seen displayed on a smartphone screen

Zenas stated that it expects to submit a Biologics License Application to the FDA in the second quarter of 2026.

AMGEN Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$28.39
Prev Close	$28.76
Open	$28.35
Dividend Yield	0.00%
50-Day Moving Average	$29.48
Beta	1.36
Avg. Volume	665,496.16
PE Ratio	-2.95

52-Week High	$44.60
52-Week Low	$13.50
Market Capitalization	$1.85B
EPS (Annual)	-$8.44
Price to Book	7.28
Revenue Per Employee	$59,880.24

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZBIO Fundamentals